{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:59:48Z","timestamp":1781056788558,"version":"3.54.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Elevated parathyroid hormone-related peptide (PTHrP) levels are often presumed to indicate malignancy-associated hypercalcemia, yet PTHrP may be elevated in nonmalignant conditions. We compared PTHrP levels in patients with known malignancies with patients with elevations of PTHrP who had defined nonmalignant diagnoses to determine which levels of PTHrP were more indicative of malignancy. A retrospective review of electronic medical records in a large midwestern hospital system was conducted using search terms hypercalcemia with elevated PTHrP (&gt;\u20092.3\u00a0pmol\/L (men) and &gt;\u20093.4\u00a0pmol\/L (women). Binary logistic regression analyses assessed the positive predictive value (PPV, probability) of cancer. Among 236 patients with hypercalcemia and elevated PTHrP, 58 had known cancer. The others had defined nonmalignant diagnoses including primary hyperparathyroidism (n\u2009=\u200987), absorptive hypercalcemia (n\u2009=\u200928), and \u201cother\u201d causes (n\u2009=\u200963). PTHrP was highest in the cancer group (PTHrP\u2009=\u200936.9, 95% CI 19.8, 53.9\u00a0pmol\/L,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), however, overlap occurred. Binary logistic regression analyses showed a positive association of PTHrP levels (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), while PTH levels were negatively associated (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) with the presence of cancer. When analyzed together, PTH on PTHrP had independent effects (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). At PTH\u2009\u2265\u200930\u00a0pg\/mL, the PPV of cancer was &lt;\u20095% when PTHrP\u2009&lt;\u20097.0\u00a0pmol\/L and &lt;\u200910% at a PTHrP\u2009&lt;\u20099.0\u00a0pmol\/L. In the evaluation of hypercalcemia with elevated PTHrP, simultaneous levels of PTH measurements improve estimation of cancer probability. Mild PTHrP elevations with PTH\u2009&gt;\u200930\u00a0pg\/mL are more consistent with nonmalignant diagnoses, although higher PTHrP levels may still warrant evaluation for occult malignancy.\n                  <\/jats:p>","DOI":"10.1007\/s00223-026-01552-4","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:18:00Z","timestamp":1781054280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Parathyroid Hormone Related Peptide (PTHrP) Revisited: A Comparison of Levels in Malignant and Non-malignant Conditions"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8635-1116","authenticated-orcid":false,"given":"Guoyu","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2575-2415","authenticated-orcid":false,"given":"Rukayat","family":"Akande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4621-6897","authenticated-orcid":false,"given":"Stewart G.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"1552_CR1","volume-title":"Williams textbook of endocrinology","author":"JP Bilezikian","year":"2025","unstructured":"Bilezikian JP, Binkley N, Goltzman D, Mannstadt M (2025) Hormones and disorders of mineral metabolism. In: Melmed S, Goldfine AB, Rosen CJ, Kopp PA (eds) Williams textbook of endocrinology. Elsevier, Amsterdam"},{"key":"1552_CR2","first-page":"766","volume-title":"Tietz textbook of laboratory medicine","author":"WD Fraser","year":"2023","unstructured":"Fraser WD (2023) Bone and mineral metabolism. In: Nader Rifai RWKC, Young I, Burnham C-AD, Wittwer CT (eds) Tietz textbook of laboratory medicine. Elsevier, Amsterdam, pp 766\u2013766"},{"key":"1552_CR3","first-page":"580","volume-title":"Brenner and rector's the kidney","author":"MSM Chonchol","year":"2020","unstructured":"Chonchol MSM, Stubbs JR, Yu ASL (2020) Disorders of calcium, magnesium, and phosphate balance. In: Alan GMC, Yu SL, Luyckx VA, Marsden PA, Skorecki K, Taal MW (eds) Brenner and rector\u2019s the kidney. Elsevier, Amsterdam, pp 580\u2013613"},{"issue":"2","key":"1552_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/clinchem\/38.2.282","volume":"38","author":"MR Pandian","year":"1992","unstructured":"Pandian MR et al (1992) Modified immunoradiometric assay of parathyroid hormone-related protein: clinical application in the differential diagnosis of hypercalcemia. Clin Chem 38(2):282\u2013288","journal-title":"Clin Chem"},{"key":"1552_CR5","first-page":"942","volume-title":"DeGroot\u2019s endocrinology","author":"D Athonvarangkul","year":"2023","unstructured":"Athonvarangkul D (2023) Malignancy-associated hypercalcemia. In: Giudice L, Robertson RP, Grossman AB, Hammer GD, Jensen MD, Kahaly GJ, Swerdloff RS, Thakker RV (eds) DeGroot\u2019s endocrinology. Elsevier, Amsterdam, pp 942\u2013954"},{"key":"1552_CR6","first-page":"818","volume-title":"DeGroot\u2019s endocrinology","author":"DY Grinman","year":"2023","unstructured":"Grinman DY (2023) Parathyroid hormone-related protein. In: Giudice L, Robertson RP, Grossman AB, Hammer GD, Jensen MD, Kahaly GJ, Swerdloff RS, Thakker RV (eds) DeGroot\u2019s endocrinology. Elsevier, Amsterdam, pp 818\u2013834"},{"issue":"10","key":"1552_CR7","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1359\/JBMR.050602","volume":"20","author":"MJ Horwitz","year":"2005","unstructured":"Horwitz MJ et al (2005) Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res 20(10):1792\u20131803","journal-title":"J Bone Miner Res"},{"key":"1552_CR8","unstructured":"ARUPLaboratories (2025) Parathyroid hormone-related peptide (PTHrP) by LC-MS\/MS, Plasma. Available from: https:\/\/ltd.aruplab.com\/Tests\/Pub\/2010677"},{"issue":"1","key":"1552_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1373\/clinchem.2015.244012","volume":"62","author":"MM Kushnir","year":"2016","unstructured":"Kushnir MM et al (2016) LC\u2013MS\/MS measurement of parathyroid hormone-related peptide. Clin Chem 62(1):218\u2013226","journal-title":"Clin Chem"},{"key":"1552_CR10","first-page":"10","volume-title":"Tietz textbook of laboratory medicine","author":"KGMM Kristian Linnet","year":"2023","unstructured":"Kristian Linnet KGMM, Boyd JC (2023) Statistical methodologies in laboratory medicine analytical and clinical evaluation of laboratory tests. In: Nader Rifai RWKC, Young I, Burnham C-AD, Wittwer CT (eds) Tietz textbook of laboratory medicine. Elsevier, Amsterdam, pp 10\u201359"},{"key":"1552_CR11","first-page":"89","volume-title":"Henry's clinical diagnosis and management by laboratory methods","author":"J Jhang","year":"2022","unstructured":"Jhang J, Lifshitz MS (2022) Postanalysis: medical decision making. In: Mcpherson RA, Pincus M (eds) Henry\u2019s clinical diagnosis and management by laboratory methods. Elsevier, Amsterdam, pp 89\u201399"},{"key":"1552_CR12","volume":"2023","author":"JA Woldemichael","year":"2023","unstructured":"Woldemichael JA, Pirela AD, Freedman BI (2023) PTH-Related protein assays in advanced kidney disease: implications for evaluation of hypercalcemia. Case Rep Nephrol 2023:6678658","journal-title":"Case Rep Nephrol"},{"issue":"6","key":"1552_CR13","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/ki.1993.193","volume":"43","author":"JJ Orloff","year":"1993","unstructured":"Orloff JJ et al (1993) Accumulation of carboxy-terminal fragments of parathyroid hormone-related protein in renal failure. Kidney Int 43(6):1371\u20131376","journal-title":"Kidney Int"},{"issue":"4","key":"1552_CR14","doi-asserted-by":"publisher","first-page":"e1115","DOI":"10.1210\/clinem\/dgz278","volume":"105","author":"T Chukir","year":"2020","unstructured":"Chukir T et al (2020) Calcitriol elevation is associated with a higher risk of refractory hypercalcemia of malignancy in solid tumors. J Clin Endocrinol Metab 105(4):e1115\u2013e1123","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1552_CR15","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf104","volume":"9","author":"ML Kometas","year":"2025","unstructured":"Kometas ML, Maalouf NM (2025) Hypercalcemia of malignancy: mechanisms and therapeutic implications of concurrently elevated PTHrP and calcitriol. J Endocr Soc 9(9):bvaf104","journal-title":"J Endocr Soc"},{"issue":"11","key":"1552_CR16","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab157","volume":"5","author":"MT Sheehan","year":"2021","unstructured":"Sheehan MT et al (2021) Evaluation of diagnostic workup and etiology of hypercalcemia of malignancy in a cohort of 167 551 patients over 20 years. J Endocr Soc 5(11):bvab157","journal-title":"J Endocr Soc"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01552-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-026-01552-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01552-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:18:06Z","timestamp":1781054286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-026-01552-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1007\/s00223-026-01552-4","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study data was considered exempt for human research by the St Louis University Institutional Review Board as the data had been anonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}],"article-number":"98"}}